Oncology Medical News about advanced solid tumors;Eribulin Mesylate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors
Clinical Cancer Research, 06/17/09

Tan AR et al. - In a trial to evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of eribulin mesylate (E7389) administered every 21 days in pts with advanced solid tumors, it was shown that eribulin mesylate has a manageable toxicity profile at 2 mg/m2, with further dose escalation limited by neutropenia.

Methods

Eribulin mesylate was given as a 1-hr infusion every 21 days at doses of 0.25, 0.5, 1, 2, 2.8, and 4 mg/m2.
The MTD was identified using an accelerated titration design.
The pharmacokinetics of eribulin were evaluated in the plasma and urine with the first dose.

Results

21 pts were enrolled.
At 4 mg/m2, 3 pts experienced a DLT of febrile neutropenia on day 7.
Dose level was reduced to 2.8 mg/m2 where 2 of 3 pts experienced dose-limiting febrile neutropenia.
6 additional pts were enrolled at 2 mg/m2 (7 pts received this dose) and 1 of these pts experienced a neutropenic DLT.
MTD of eribulin mesylate was 2 mg/m2.
Nonhematologic toxicities included alopecia, fatigue, anorexia, and nausea.
Pharmacokinetic analysis showed linear kinetics for eribulin over the dose range studied and a terminal half-life of 2 days.
Plasma-concentration-time profile exhibited a rapid distribution phase followed by a slow elimination phase.
Drug clearance was nonrenal.
1 pt with non–small cell lung cancer achieved an unconfirmed partial response and 12 pts had stable disease.